Evaluating the Role of Steroid-Sparing Treatment Approaches in Pediatric Atopic Dermatitis

Evaluating the Role of Steroid-Sparing Treatment Approaches in Pediatric Atopic Dermatitis

On-Demand Webcast
FACULTY

Robert Sidbury, MD, MPH - Chair
Professor, Department of Pediatrics
Chief, Division of Dermatology
Seattle Children's Hospital
University of Washington School of Medicine
Seattle, Washington

Peter A. Lio, MD
Clinical Assistant Professor
Dermatology and Pediatrics
Northwestern University Feinberg School of Medicine, Chicago
Chicago, Illinois

Wynnis Tom, MD
Clinical Professor of Dermatology and Pediatrics
Fellowship Program Director
Pediatric & Adolescent Dermatology
Rady Children's Hospital/University of California, San Diego
San Diego, California

PROVIDER STATEMENT

Provided by North American Center for Continuing Medical Education, LLC, an HMP Company.

For questions regarding this educational activity, please call 609-371-1137 or email info@naccme.com.

INTENDED LEARNERS

This activity is designed for pediatricians and PCPs, as well as nurse practitioners and physician assistants and other HCPs who care for pediatric patients with AD.

lEARNING OBJECTIVES

After participating in this activity, participants should be better able to:

  • Describe psychosocial and quality-of-life effects of atopic dermatitis on pediatric patients and their caregivers/families.
  • Outline the pathophysiologic correlations between atopic dermatitis and other allergic and immune diseases.
  • Discuss guideline recommendations for limiting the use of topical and systemic steroidal medications in pediatric patients.
  • Review the efficacy and safety profiles of nonsteroidal treatments available for pediatric atopic dermatitis.
  • Incorporate pediatric atopic dermatitis treatment pathway recommendations into clinical practice.
claiming crediT

This webcast is based on live proceedings from a symposium conducted at the 51st ASHP Midyear Clinical Meeting and Exhibition.

Participants who have successfully completed the live version of this activity are not eligible to receive credit for this enduring material.

To be eligible for credit, participants must complete the online activity, a post-test assessment, and the evaluation by November 7, 2020. Upon completing the activity, there will be instructions on how to print a certificate or other documentation of credit.

Release Date: November 7, 2019
Expiration Date: November 7, 2020
Estimated Time to Complete: 1.5 hours

There is no fee associated with this activity.

This educational activity is a knowledge-based activity.

For questions regarding this educational activity, please call 609-371-1137.

This symposium is neither sponsored nor endorsed by the American Academy of Pediatrics.

COMMERCIAL SUPPORT

NACCME would like to thank the following company who has supported the "Evaluating the Role of Steroid-Sparing Treatment Approaches in Pediatric Atopic Dermatitis" through educational grants and/or in-kind support: Pfizer

CONTINUING EDUCATION

    In support of improving patient care, NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIANS

NACCME designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

nursing

This continuing nursing education activity awards 1.50 contact hours.

Provider approved by the California Board of Registered Nursing, Provider #13255 for 1.50 contact hours.

PHYSICIAN ASSISTANTS

NACCME has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1.50 CME credits for activities planned in accordance with the AAPA CME Criteria. This activity is designated for 1.50 AAPA Category 1 credits. PAs should only claim credit commensurate with the extent of their participation.

USE OF PROPRIETARY NAMES

This continuing medical education activity may include device or medicine brand names for participant clarity purposes only, due to the presence of different branded versions of the same product. No product promotion or recommendation should be inferred.

UNAPPROVED AND/OR INVESTIGATIONAL USES OF DRUGS AND DEVICES

This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the European Medicines Agency (EMA) of the European Union or the Food and Drug Administration (FDA) of the United States. Participants are strongly encouraged to consult approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed during this activity are the opinions of the respective authors, presenters or moderators and do not necessarily reflect the opinions of NACCME.

DISCLAIMERS

The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.

Neither NACCME nor any of its subsidiaries or affiliates is affiliated with, or formally endorsed by a medical society.

The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME or HMP. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.

DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS

NACCME, LLC is an independent provider(s) of continuing medical education. NACCME, LLC has no proprietary or financial interest in medical or healthcare products over which the FDA (USA) or EMA (EU) has regulatory authority.

NACCME, LLC assures that all educational materials are reviewed to ensure for the absence of commercial bias, fair balance, scientific objectivity, and levels of evidence. The educational activity will not be influenced by commercial organizations and will not conflict with any other scheduled educational activities.

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

Clinical Reviewers

Joseph C. English III, MD
Prof. of Dermatology
Medical Director of Teledermatology
UPMC North Hills Dermatology
Wexford, Pennsylvania

Planning Committee

In addition to the faculty listed below, NACCME planners and staff include Angelica Archibald, Chris Boswell, Mary Johnson, Jennifer Ilcyn, Todd Klunker, Randy Robbin and Margie Stefan.

Mr. Bolwell is a shareholder of GlaxoSmithKline. GlaxoSmithKline is not supporting this activity, nor does any content relate to their product/service.

Faculty
The faculty has reported the following:

Dr. Lio: Grant/Research Support–AbbVie, AOBiome LLC, Genzyme, Regeneron/Sanofi; Consultant–AbbVie, AOBiome, Altus Labs, Dermavant, Dermira, Eli Lilly, Exeltis, Franklin Bioscience, Galderma, Genzyme, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L'Oreal, Menlo, Mission, Micreos, Pfizer, Pierre Fabre, Realm, Regeneron/Sanofi, Theraplex, TopMD, UCB, Unilever, Valeant, Verrica; Speakers' Bureau–Galderma, Genzyme, Johnson & Johnson, L'Oreal, Pfizer, Pierre-Fabre, Regeneron/Sanofi, TopMD

Dr. Sidbury: Grant/Research Support–Brickell, Regeneron; Consultant–Micreos, Pfizer

Dr. Tom: Clinical Trial Investigator–Incyte, Janssen, Pfizer, Regeneron; Safety Committee Member–LEO Pharma

Dr. English has disclosed no relevant financial relationships with any commercial interests.

ADA STATEMENT

North American Center for Continuing Medical Education (NACCME) complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please call 609-371-1137.

PRIVACY POLICY

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint providers. NACCME and our joint providers will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency. NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2019 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education.